Difference between revisions of "Part:BBa K4165152"
Line 5: | Line 5: | ||
Tau binding peptide targeting the PHF seed of Tau | Tau binding peptide targeting the PHF seed of Tau | ||
− | + | ||
===Usage and Biology=== | ===Usage and Biology=== | ||
+ | |||
+ | ISAD1 peptide with amino acid sequence of SVFKLSLTDAAS. It acts as an inhibitor for wild type full length tau aggregation. | ||
<!-- --> | <!-- --> | ||
Line 12: | Line 14: | ||
<partinfo>BBa_K4165152 SequenceAndFeatures</partinfo> | <partinfo>BBa_K4165152 SequenceAndFeatures</partinfo> | ||
+ | ===Dry Lab=== | ||
+ | |||
+ | <p style=" font-weight: bold; font-size:14px;"> Modeling </p> | ||
+ | |||
+ | ISAL1 is modeled by AlphaFold2, Apptest, ITASSER, best model obtained from Apptest. | ||
+ | |||
+ | |||
+ | |||
+ | |||
+ | <html> | ||
+ | <p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/isad1.png" style="margin-left:200px;" alt="" width="300" /></p> | ||
+ | </html> | ||
+ | |||
+ | Figure 1.: Predicted 3D structure of Synthetic peptide ISAD1. | ||
+ | |||
+ | |||
+ | |||
+ | <p style=" font-weight: bold; font-size:13px;"> Table 1: Quality assessment parameters of ISAD1 model. </p> | ||
+ | |||
+ | <html> | ||
+ | <p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/isal1-qa.png" style="margin-left:75px;" alt="" width="800" /></p> | ||
+ | </html> | ||
+ | |||
+ | |||
+ | ===References=== | ||
+ | 1. Aillaud, I., Kaniyappan, S., Chandupatla, R. R., Ramirez, L. M., Alkhashrom, S., Eichler, J., ... & Funke, S. A. (2022). A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro. Alzheimer's research & therapy, 14(1), 1-19. | ||
<!-- Uncomment this to enable Functional Parameter display | <!-- Uncomment this to enable Functional Parameter display |
Revision as of 18:04, 5 October 2022
ISAD1 Peptide
Tau binding peptide targeting the PHF seed of Tau
Usage and Biology
ISAD1 peptide with amino acid sequence of SVFKLSLTDAAS. It acts as an inhibitor for wild type full length tau aggregation.
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Dry Lab
Modeling
ISAL1 is modeled by AlphaFold2, Apptest, ITASSER, best model obtained from Apptest.
Figure 1.: Predicted 3D structure of Synthetic peptide ISAD1.
Table 1: Quality assessment parameters of ISAD1 model.
References
1. Aillaud, I., Kaniyappan, S., Chandupatla, R. R., Ramirez, L. M., Alkhashrom, S., Eichler, J., ... & Funke, S. A. (2022). A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro. Alzheimer's research & therapy, 14(1), 1-19.